Timo M. Blomster

Oulu, Finland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Uniformity Between Serological Biomarker Test, Esophago-gastro-duodenoscopy and Biopsy Histology in Triage of Upper Abdominal Symptoms in Gastroscopy Referral Patients.

Uniformity Between Serological Biomarker Test, Esophago-gastro-duodenoscopy and Biopsy Histology in Triage of Upper Abdominal Symptoms in Gastroscopy Referral Patients.

Journal: Anticancer research

Published: August 29, 2025

Pregnancy period and early-life risk factors for inflammatory bowel disease: a Northern Finland birth cohort 1966 study.

Pregnancy period and early-life risk factors for inflammatory bowel disease: a Northern Finland birth cohort 1966 study.

Journal: BMC public health

Published: December 20, 2023

Real-life treatment persistence and treatment outcomes of Finnish patients with inflammatory bowel disease receiving vedolizumab as first-line biological treatment.

Real-life treatment persistence and treatment outcomes of Finnish patients with inflammatory bowel disease receiving vedolizumab as first-line biological treatment.

Journal: Heliyon

Published: October 17, 2023

Serological Biomarker Panel in Diagnosis of Atrophic Gastritis and Helicobacter pylori Infection in Gastroscopy Referral Patients: Clinical Validation of the New-Generation GastroPanel® Test.

Serological Biomarker Panel in Diagnosis of Atrophic Gastritis and Helicobacter pylori Infection in Gastroscopy Referral Patients: Clinical Validation of the New-Generation GastroPanel® Test.

Journal: Anticancer research

Published: September 04, 2021

Characterization of inflammatory bowel disease management by vedolizumab and concomitant treatments in real-life clinical practice.

Characterization of inflammatory bowel disease management by vedolizumab and concomitant treatments in real-life clinical practice.

Journal: Biologicals : journal of the International Association of Biological Standardization

Published: October 17, 2018

High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab - a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO).

High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab - a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO).

Journal: Scandinavian journal of gastroenterology

Published: December 21, 2017

Long-term outcome of inflammatory bowel disease patients with deep remission after discontinuation of TNFα-blocking agents.

Long-term outcome of inflammatory bowel disease patients with deep remission after discontinuation of TNFα-blocking agents.

Journal: Scandinavian journal of gastroenterology

Published: November 04, 2016

Does fecal calprotectin predict short-term relapse after stopping TNFα-blocking agents in inflammatory bowel disease patients in deep remission?

Does fecal calprotectin predict short-term relapse after stopping TNFα-blocking agents in inflammatory bowel disease patients in deep remission?

Journal: Journal of Crohn's & colitis

Published: July 24, 2014

Outcome after discontinuation of TNFα-blocking therapy in patients with inflammatory bowel disease in deep remission.

Outcome after discontinuation of TNFα-blocking therapy in patients with inflammatory bowel disease in deep remission.

Journal: Inflammatory bowel diseases

Published: May 07, 2014

Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.

Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.

Journal: Journal of Crohn's & colitis

Published: June 12, 2012

Showing 1-10 of 10

Last Updated: 09/26/2026